Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capivasertib Plus Immunotherapy in Advanced Bladder Cancer
NCT07793578Phase 2Not yet recruiting
- Sponsor
- VA Office of Research & Development
- Start
- Jan 2027
- Primary completion
- Sep 2029
- Countries
- 1
01
Overview
A Phase 2 trial of capivasertib in urothelial carcinoma (UC), sponsored by VA Office of Research & Development. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
capivasertib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT07793578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07793578.